Celcuity Inc. (NASDAQ:CELC) Shares Acquired by Barclays PLC

Barclays PLC increased its holdings in shares of Celcuity Inc. (NASDAQ:CELC) by 567.6% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 53,605 shares of the company’s stock after acquiring an additional 45,576 shares during the period. Barclays PLC owned approximately 0.14% of Celcuity worth $800,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. nVerses Capital LLC acquired a new position in Celcuity during the third quarter worth $33,000. Prospera Private Wealth LLC purchased a new stake in shares of Celcuity during the third quarter worth about $35,000. Values First Advisors Inc. acquired a new position in shares of Celcuity during the 3rd quarter worth about $86,000. Quest Partners LLC lifted its stake in Celcuity by 31.3% in the 2nd quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock valued at $95,000 after buying an additional 1,379 shares in the last quarter. Finally, SG Americas Securities LLC purchased a new position in Celcuity in the 3rd quarter valued at about $119,000. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity Price Performance

NASDAQ:CELC opened at $13.09 on Wednesday. Celcuity Inc. has a one year low of $11.51 and a one year high of $22.19. The stock has a market cap of $486.03 million, a PE ratio of -5.02 and a beta of 0.74. The company has a debt-to-equity ratio of 0.65, a quick ratio of 10.36 and a current ratio of 10.35. The stock has a 50 day moving average price of $13.68 and a 200 day moving average price of $15.31.

Analyst Upgrades and Downgrades

A number of brokerages have commented on CELC. Stifel Nicolaus increased their target price on Celcuity from $39.00 to $42.00 and gave the company a “buy” rating in a report on Monday, October 7th. Needham & Company LLC reiterated a “buy” rating and set a $23.00 price target on shares of Celcuity in a research report on Friday, November 15th. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a report on Friday, November 15th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $29.17.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.